By bioinformatics analysis, METTL14 protein levels were significantly lower in renal tumor tissues than in paired normal tissues, and low levels of METTL14 enhanced the stability of bromodomain PHD finger transcription factor (BPTF), and accumulated BPTF constituted and reinforced enhancers or super-enhancers (SEs) activating enolase 2 (ENO2) and SRC proto-oncogene nonreceptor tyrosine kinase (SRC), leading to glycolytic reprogramming and triggering the aerobic glycolytic pathway, thus promoting RCC metastasis in vitro and in vivo (133). The gene discussed is METTL14; the disease is renal cell carcinoma.